Safety, tolerability and pharmacokinetics of an NMDA receptor subunit 2B-selective negative allosteric modulator, BI 1569912: Results of three partially randomised, placebo-controlled phase I trials.

BI 1569912 - Boehringer Ingelheim

http://www.ncbi.nlm.nih.gov/pubmed/42684025

Akiko Harada; Andreas Hünnemeyer; Andreas Scholz; Christian Keicher; Franco De Crescenzo; Rainer-Georg Goeldner; Sigurd D Süssmuth; Tetsuya Katakabe; Yoichiro Ogama; Yury Shatillo

Sep 3, 2026